July 13, 2022 News by Marisa Wexler, MS Women with MS More Likely to Be Sexually, Emotionally Abused Rates of sexual and emotional abuse are higher in women with multiple sclerosis (MS) compared with women in the general population, according to a new study from Norway. These women are also at more than two times higher risk of being revictimized, which occurs when a person who has…
July 12, 2022 News by Marisa Wexler, MS Aubagio May Significantly Lower Relapse Risk in Children With MS Treatment with Aubagio (teriflunomide) may significantly reduce the risk of relapse in children with multiple sclerosis (MS), according to a new analysis of the TERIKIDS clinical trial that took into account data from adult trials. Results wereĀ in the paper “Reinterpreting Clinical Trials in Children With…
July 11, 2022 News by Marisa Wexler, MS Early MS Symptoms May Help Predict Diagnosis, Disease Course Some prodromal symptoms of multiple sclerosis (MS) ā symptoms that are evident before the disease begins in earnest ā could help to predict the course of MS, a new study proposes. In particular, its researchers suggest that MS patients with prodromal depression are more likely to be diagnosed…
July 8, 2022 News by Marisa Wexler, MS Levels of Certain Inflammatory Proteins May Predict Risk of Relapse Levels of certain inflammatory proteins in the cerebrospinal fluid, the liquid around the brain and spinal cord, may help predict the risk of relapse activity for individuals with early multiple sclerosis (MS), a new study found. High levels of three such proteins were predictive of a greater risk of…
July 6, 2022 News by Marisa Wexler, MS Researchers Distinguish Remyelinated Brain Lesions Via MRI An MRI technique called quantitative susceptibility mapping (QSM) can be used to accurately identify remyelinated brain lesions in people with multiple sclerosis (MS), a research team has discovered. Remyelinated lesions are those in which the myelin sheath ā the protective coating around nerve fibers that is progressively lost…
July 1, 2022 News by Marisa Wexler, MS Efficacy, Safety of Mavenclad in Real World Similar to That of Trials The safety and efficacy of the approved multiple sclerosis (MS)Ā therapy Mavenclad (cladribine) in a real-world group of patients were similar to what had been demonstrated in clinical trials, a new study reports. Among 243 people with relapsing-remitting multiple sclerosis (RRMS), more than 60% showed no…
June 30, 2022 News by Marisa Wexler, MS Long-term Zeposia May Help Cognitive Function in Patients, Data Show Long-term treatment with Zeposia (ozanimod) stabilizes or even improves cognitive function in adults with relapsing forms of multiple sclerosis (MS), particularly among those with greater brain volumes. Thatās according to five years of data from the completed SUNBEAM Phase 3 clinical trial (NCT02294058) and the ongoing…
June 28, 2022 News by Marisa Wexler, MS No Disease Activity After 4 Years for Nearly 80% of Patients on Kesimpta People with relapsing forms of multiple sclerosis (MS) who were continuously on Kesimpta (ofatumumab) for up to four years were about four times more likely to have no evidence of disease activity than those initially on Aubagio (teriflunomide), according to updated data from the ASCLEPIOS and ALITHIOS…
June 27, 2022 News by Marisa Wexler, MS Proteins Called Tenascins Found to Block Myelin Repair in Mouse Model Proteins called tenascins block the regeneration of myelin by modulating the activity of oligodendrocytes, myelin-making cells of the central nervous system, a study in mouse modelsĀ indicates. “Our research results open up new therapeutic approaches for the treatment of demyelinating diseases such as multiple sclerosis,” Juliane Bauch, a researcher at Ruhr-University…
June 21, 2022 News by Marisa Wexler, MS T-cells in Bone Marrow Work to Drive Inflammatory MS Attacks Unusual growth in anĀ immune cell classĀ called myeloid cells is evident in the bone marrow of people with multiple sclerosis (MS), and these cells likely contribute to the inflammation that drives the disease, according to a new study. Experiments in mice suggest that myelin-reactive T-cells can migrate to the bone…
June 20, 2022 News by Marisa Wexler, MS Neural Sleeve Improves Mobility, Reduces Pain and Depression: Cionic Cionic‘s leg-worn Neural Sleeve, recently authorized in the U.S. to aid walking in people with multiple sclerosis (MS) and other conditions that impair mobility, reduced foot drop in a small clinical trial. Patients in the trial also reported marked reductions in pain and mental health problems, according to…
June 17, 2022 News by Marisa Wexler, MS Vidofludimus Calcium Safely Reduced RRMS Brain Lesions Treatment with the experimental immune-modulating therapy vidofludimus calcium reduced disease activity on MRI scans in adults with relapsing-remitting multiple sclerosisĀ (RRMS), data from the Phase 2 EMPhASIS clinical trial shows. Top-line results from EMPhASIS were reported by the therapy’s developer Immunic Therapeutics in 2020. Researchers at…
June 16, 2022 News by Marisa Wexler, MS 2nd SPMS Patient Sees Clinical Gains With Foralumab Treatment Treatment with foralumab nasal spray resulted in marked clinical improvements after three months in the second secondary progressive multiple sclerosis (SPMS) patient treated under a single-patient access program. The findings were generally consistent with those seen in the first SPMS patient and supported a decision by the U.S. Food…
June 13, 2022 News by Marisa Wexler, MS MS Tied to 75% Increased Risk of Mortality in US Study The overall risk of death is about 75% higher for people with multiple sclerosis (MS) than in the general population, according to a new study. “The association was independent of demographic, socioeconomic variables, lifestyle factors, baseline diabetes, cardiovascular disease, chronic respiratory disease, and cancer status,” researchers wrote. The study,…
June 8, 2022 News by Marisa Wexler, MS Cancer Therapy Topotecan Could Be Repurposed to Treat MS: Study A medication currently approved to treat certain kinds of cancer, called topotecan, could be repurposed for treating neuroinflammatory conditions such as multiple sclerosis (MS) because it reduces the inflammatory activity of immune cells called microglia. That’s according to the study, “Myeloid cell-specific topoisomerase 1 inhibition using DNA origami…
June 7, 2022 News by Marisa Wexler, MS No Disease Activity for 58% of Those on Aubagio After 2 Years: Study More than half of the people with multiple sclerosis (MS) treated withĀ Aubagio (teriflunomide) showed no evidence of disease activity after two years on treatment, according to aĀ study in Italy. The study, “Evolution of teriflunomide use in multiple sclerosis: A real-world experience,” was published in theĀ Journal of…
June 1, 2022 News by Marisa Wexler, MS FDA Decision on Ublituximab for Relapsing MS Pushed to Year’s End The U.S. Food and Drug Administration (FDA) is extending by three months its review ofĀ ublituximab, an experimental anti-CD20 antibody being developed by TG Therapeutics for relapsing forms of multiple sclerosis (MS). The FDA had agreed to review the company’s application requesting ublituximab’s approval late last year, and…
June 1, 2022 News by Marisa Wexler, MS New Scale May Better Assess MS Changes, Therapy Response in Mice A new scoring system might more precisely evaluate disease development, severity, and treatment response in a commonly used mouse model of multiple sclerosis (MS) known as the experimental autoimmune encephalomyelitis or EAE model, scientists report. This scoring system, called “I AM D EAE,”Ā was described in the study, “…
May 27, 2022 News by Marisa Wexler, MS BBB Leakiness Decrease May Predict Effectiveness of Lemtrada Treatment Among multiple sclerosis (MS) patients starting on Lemtrada (alemtuzumab), an early decrease in the leakiness of the blood-brain barrier (BBB) is associated with a lower likelihood of disease activity after two years, according to a new study. The blood-brain barrier is a cellular divisor that regulates which substances…
May 26, 2022 News by Marisa Wexler, MS Ponvory Reduces Risk of Worsening Disability Over Placebo Treatment with Ponvory (ponesimod) significantly reduces the risk of worsening disability or new relapses for people with relapsing forms of multiple sclerosis (MS) compared with a placebo, according to a new analysis funded by the therapy’s maker Janssen. The study,Ā “Comparative Efficacy of Relapsing Multiple Sclerosis Therapies:…
May 26, 2022 News by Marisa Wexler, MS Lesions in 3 Brain Regions Can Help Distinguish MS From Like Disorders People with multiple sclerosis (MS) are more likely to have lesions in three regions of the brain ā the anterior temporal horn, periventricular region, and cerebellar hemisphere ā compared with people with other inflammatory brain diseases, a study reports. Looking for lesions in these parts of the brain may…
May 19, 2022 News by Marisa Wexler, MS Preclinical Data Support Remyelinating Potential of ABX-002 ABX-002, an experimental treatment for multiple sclerosis (MS) being developed by Autobahn Therapeutics, promoted the restoration of the myelin sheath in preclinical models of the disease, new data show. The research, which specifically tested an analog of ABX-002 called LL-341070, will be presented by Autobahn’s academic collaborators at…
May 18, 2022 News by Marisa Wexler, MS Marriage, Education, DMT Affect Patients’ Treatment Adherence Among people with relapsing-remitting multiple sclerosis (RRMS), those who are married and have more formal education are more likely to take treatments as recommended, according to a new study from Iran. The study, “Effects of Disease-Modifying Treatments discontinuation in patients with Relapsing-Remitting Multiple Sclerosis: A 5…
May 17, 2022 News by Marisa Wexler, MS ‘Hidden’ Disabilities Fairly Common at RRMS Diagnosis, Study Finds Many people newly diagnosed withĀ relapsing-remitting multiple sclerosis (RRMS) experience substantial “hidden disabilities,” such as depression or fatigue, a study highlights. Findings indicate that treatment with disease-modifying therapies generally does not affect the severity of these problems, at least in the short term. “Considering the substantial impact that hidden…
May 16, 2022 News by Marisa Wexler, MS With Rituximab, B-cell Counts Predict COVID-19 Vaccine Response Among multiple sclerosis (MS) patients on rituximab, higher B-cell counts are predictive of a better antibody-based response to a vaccine for COVID-19, according to a new Swedish study. “In our study, the B-cell level in patients given Rituximab was the only factor that influenced the ability to form antibodies…
May 11, 2022 News by Marisa Wexler, MS Treatment With XPro1595 Promotes Remyelination in Mouse Model The experimental therapy XPro1595 was found to promote remyelination ā the repair of the myelin sheath ā in a mouse model of myelin loss, new data show. Myelin, the fatty covering that helps nerve fibers send electrical signals, is damaged by the immune system inĀ …
May 6, 2022 News by Marisa Wexler, MS Keto Diet Improved Life Quality of RRMS Patients in Trial Eating a ketogenic diet ā one low in carbohydrates and high in fats ā led to markedly less fatigue and depression for people with relapsing-remitting multiple sclerosis (RRMS) in a small clinical trial that was designed to assess the tolerability of the dietary intervention. Measures of disability and quality…
May 5, 2022 News by Marisa Wexler, MS Study Finds New Molecules Targeted by the Immune System Researchers have identified four new brain proteins that are targeted by inflammatory T-cells in multiple sclerosis (MS), which could aid in the development of more specific and safer treatments for people with the condition. The study, “Identification of four novel T cell autoantigens and personal autoreactive profiles in…
May 4, 2022 News by Marisa Wexler, MS Cannabis ‘Highly Effective’ Against MS Symptoms, Some Users Report More than half of Canadians with multiple sclerosis (MS) report using cannabis to help manage their symptoms, according to a new study. The study,Ā “Medical cannabis use in Canadians with multiple sclerosis,” was published in Multiple Sclerosis and Related Disorders. Humans have used the cannabis plant for millennia,…
May 3, 2022 News by Marisa Wexler, MS Tysabri Every 6 Weeks Found as Effective as Standard 4-week Dosing Tysabri (natalizumab) given every six weeks was found to be similarly effective as the standard four-week dosing schedule at stopping nervous system damage in people with relapsing-remitting multiple sclerosis (RRMS). That’s according to the full results of the Phase 3b NOVA clinical trial, which compared Tysabri dosing schedules…